Disease Studies

Systematic drug repurposing to enable precision medicine: A case study in breast cancer

Precision medicine and drug repurposing provide an opportunity to ameliorate the challenges of declining pharmaceutical R&D productivity, rising costs of new drugs, and poor patient response rates to existing medications. Multifactorial “disease signatures” provide unique insights into the architecture of complex disease populations that can be used to better stratify patient groups, aiding the delivery of precision medicine.

Analysis of a complex disease (breast cancer) population was undertaken to identify the combinations of single‑nucleotide polymorphisms that are associated with different disease subgroups. Target genes associated with the disease risk of these subgroups were examined, followed by identification and evaluation of existing active chemical leads as drug repurposing candidates.

One hundred and seventy‑five disease‑associated gene targets relevant to different subpopulations of breast cancer patients were identified. Twenty‑three of these genes were prioritized as both promising novel drug targets and repurposing candidates. Two targets, P4HA2 and TGM2, have high repurposing potential and a strong mechanistic link to breast cancer.

This study showed that detailed analysis of combinatorial genomic (and other) features can be used to accurately stratify patient populations and identify highly plausible drug repurposing candidates systematically across all disease‑associated targets.

To view the publication in full, please see https://www.digitmedicine.com/article.asp?issn=2226-8561;year=2019;volume=5;issue=4;spage=180;epage=186;aulast=Taylor

More News & Media

View All News & Media

Why does chronic disease drug discovery & development need fixing?

The blockbuster model for drug discovery and development in chronic diseases is inefficient and costly. We need a new…

Read more

Anyone for tea? Why Alzheimer’s drug discovery might be targeting the impossible

Unique approach to precision medicine could reverse the trend in Alzheimer’s disease drug discovery and development Clinical trials in…

Read more

Complexity of disease biology gives opportunities for drug discovery

Late-stage clinical trials incur the biggest costs of bringing new drugs to market. Increasingly clinical trial failures happen late….

Read more

Keep in touch

Please enter your email address if you would like to be kept informed of our work here at PrecisionLife. Note that our Privacy Policy and Terms & Conditions apply.

Contact us

If you have any questions or would like to speak to us in terms of potential collaborations or partnership opportunities, please get in touch using the form below or email info@precisionlife.com and we will get back to you as soon as we can. Note that our Privacy Policy and Terms & Conditions apply.


Unit 8b Bankside
Hanborough Business Park
Long Hanborough, OX29 8LJ


1 Broadway Fl 14
MA 02142-1187


Agern Allé 3


Chmielna 73m
00-801 Warszawa